Concizumab May Be Effective Prophylaxis for Hemophilia A or B With Inhibitors
Overall median annualized bleeding rate was 0 with concizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Overall median annualized bleeding rate was 0 with concizumab
Only registered members have full access to PracticeUpdate content.